Answers are grounded in this paper and cite their sources.
Background: Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet production. The programmed death-1 (PD-1) pathway is an important immune checkpoint involved in maintaining peripheral tolerance. Objective: To evaluate serum soluble PD-1 (sPD-1) levels in adult patients with immune thrombocytopenia and assess their relationship with disease duration and clinical severity. Methods: This cross-sectional study included 50 adult patients with primary immune thrombocytopenia and 30 healthy controls recruited from Merjan Teaching Hospital and Al-Imamain Al-Kadhimain Medical City between January and December 2025. Serum sPD-1 levels were measured using enzyme-linked immunosorbent assay. Statistical analysis was performed using SPSS version 26. Results: Serum sPD-1 levels were significantly lower in ITP patients than in healthy controls (p < 0.001). Lower sPD-1 levels were associated with longer disease duration. No significant association was observed between sPD-1 levels and thrombocytopenia severity or bleeding severity. Conclusion: Reduced serum sPD-1 levels in adult ITP may reflect impaired immune checkpoint regulation and appear to be associated with disease chronicity rather than disease severity.
No takes yet. Share an insight, caveat, or question.
Asad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: